Federated Global Investment Manag.. has recently announced that it has increased stake in Dynavax Technologies Corporation (NASDAQ:DVAX) by 14.33%. After grabbing 11.17 million shares, the institutional investor is now in possession of 1.4 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.52% having worth around $90.56 million. Moreover, BlackRock Fund Advisors increased its share by 0.92 million to have a control over 6.16 million shares. And Redmile Group LLC raised its holdings to 5.06 million shares by acquiring 5.06 million shares or 4.77% of the stake.

Dynavax Technologies Corporation (DVAX) concluded trading on 08/27/20 at a closing price of $6.00, with 3.04 million shares of worth about $18.21 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -10.45% during that period and on Thursday the price saw a loss of about -3.85%. Currently the company’s common shares owned by public are about 109.51M shares, out of which, 97.74M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the DVAX stock and their offered price forecasts bring an average price target of $12.91. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $20.00 and could fall to a lowest price of $6.72. Analysts also issued an outlook of 1.70 for the Dynavax Technologies Corporation stock for next 12 months. However, touching the estimated high of $20.00 would mean a gain of 70.0% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 25 times over the past 12 months. They bought 180,958 shares in 13 of the transactions. In 12 selling transactions, insiders dumped 190,053 shares.

Federated Hermes Kaufmann Fund, Federated Hermes Kaufmann Small C, and SPDR S&P Biotech ETF are the top 3 mutual funds which are holding stakes in Dynavax Technologies Corporation Federated Hermes Kaufmann Fund is currently holding 6.17 million shares of worth totaling $50.08 million. The company recently came buying 0.78 million shares which brought its stake up to 5.82% of the company’s outstanding shares. Federated Hermes Kaufmann Small C bought 0.6 million shares, after which its hold over company’s outstanding shares expand to 4.54%, leaving 4.83 million shares with the mutual fund that have a worth of about $39.13 million. SPDR S&P Biotech ETF, after selling 3.58 million shares, have now control over 3.37% of the stake in the company. It holds 35826.0 shares of worth $29.0 million.

Dynavax Technologies Corporation (NASDAQ: DVAX) started trading at $6.22, below -$0.02 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $6.00, or with a loss of -3.85%. Stock saw a price change of -10.45% in past 5 days and over the past one month there was a price change of -24.72%. Year-to-date (YTD), DVAX shares are showing a performance of 4.90% which increased to 46.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.80 but also hit the highest price of $12.44 during that period. While comparing its average daily trading volume of 7.14 million shares, we see that about 3.04 million changed hands on the day. The stock is currently trading -18.54% below its 20-day simple moving average (SMA20), while that difference is down -26.61% for SMA50 and it goes to 4.22% higher than SMA200.

Federated Global Investment Manag.. acquired 11.17 million shares of Dynavax Technologies Corporation having value of about $90.56 million. Data submitted at the U.S SEC by Federated Global Investment Manag.. revealed that the firm now holds 1.4 million shares in the company valued at close to $8400000.0, or have control over 14.33% stake in the company. Dynavax Technologies Corporation (NASDAQ: DVAX) currently have 109.51M outstanding shares and institutions hold larger chunk of about 74.40% of that. Holding of mutual funds in the company is about 32.95% while other institutional holders and individual stake holders have control over 34.16% and 0.90% of the stake respectively.

The stock has a current market capitalization of $678.30M and its 3Y-monthly beta is at 1.09. It has posted earnings per share of -$1.60 in the same period. It has Quick Ratio of 4.00 while making debt-to-equity ratio of 3.08. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DVAX, volatility over the week remained 7.53% while standing at 8.99% over the month.

Analysts are in expectations that Dynavax Technologies Corporation (DVAX) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter ESPS is -$0.19 and it is -$0.65 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.24 which is -$0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.49 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 15.10% while it is estimated to increase by 42.00% in next year.

Analysts at 4 brokerage firms have issued recommendations for the Dynavax Technologies Corporation (DVAX)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 4 Wall Street analysts, 4 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on August 07, 2020 offering a Buy rating for the stock and assigned a target price range of between $14 and $12 to it. Coverage by H.C. Wainwright stated Dynavax Technologies Corporation (DVAX) stock as a Buy in their note to investors on August 03, 2020, suggesting a price target of $14 for the stock. On June 15, 2020, Evercore ISI Initiated their recommendations, while on October 18, 2019, H.C. Wainwright Initiated their ratings for the stock with a price target of $13. Stock get an Overweight rating from Cantor Fitzgerald on July 11, 2019.